Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 9:39 PM
Ignite Modification Date: 2025-12-24 @ 9:39 PM
NCT ID: NCT03328832
Eligibility Criteria: Inclusion Criteria: 1. Patients who have advanced knee osteoarthritis are scheduled to undergo primary, unilateral elective total knee replacement surgery 2. Age \> 50 years and \< 90 years 3. Failure of medical treatment or rehabilitation. 4. Hemoglobin \> 11g/dl, 5. No use of non-steroid anti-inflammatory agent one week before operation Exclusion Criteria: 1. Preoperative Hemoglobin ≦11 g/dl 2. History of infection or intraarticular fracture of the affective knee 3. Renal function deficiency (GFR \<30 ml/min/1.73m2)which is relative contraindicated for chemical venous thromboembolism 4. Elevated liver enzyme (AST/ALT level are more than twice normal range) , history of liver cirrhosis, impaired liver function(elevated total bilirubin level) and coagulopathy (including long-term use anticoagulant) 5. History of deep vein thrombosis, ischemic heart disease or stroke 6. Contraindications of tranexamic acid, floseal, or rivaroxaban 7. Allergy to tranexamic acid, floseal, rivaroxaban, or the excipients 8. History of heparin-induced thrombocytopenia (HIT) 9. Coagulopathy or bleeding tendency caused by organ dysfunction, such as cirrhosis, bone marrow suppression etc. 10. Patient who have active bleeding disorder, such as intracranial hemorrhage, upper GI bleeding, hematuria. 11. Patients with known allergies to materials of bovine origin
Healthy Volunteers: True
Sex: ALL
Minimum Age: 50 Years
Maximum Age: 90 Years
Study: NCT03328832
Study Brief:
Protocol Section: NCT03328832